Literature DB >> 28575396

BLAST-AHF: insights into biased AT1 ligands and heart failure. Beginning of the end or end of the beginning?

Shinobu Sugihara1, John C Burnett1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28575396      PMCID： PMC5837525          DOI： 10.1093/eurheartj/ehx276

Source DB:  PubMed          Journal:  Eur Heart J        ISSN： 0195-668X            Impact factor:   29.983


× No keyword cloud information.
  14 in total

1.  Cardiorenal actions of TRV120027, a novel ß-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure.

Authors:  Guido Boerrigter; Michael W Lark; Erin J Whalen; David G Soergel; Jonathan D Violin; John C Burnett
Journal:  Circ Heart Fail       Date:  2011-08-11       Impact factor: 8.790

Review 2.  Beta-arrestins and cell signaling.

Authors:  Scott M DeWire; Seungkirl Ahn; Robert J Lefkowitz; Sudha K Shenoy
Journal:  Annu Rev Physiol       Date:  2007       Impact factor: 19.318

3.  Cardiovascular disease in Europe: epidemiological update 2016.

Authors:  Nick Townsend; Lauren Wilson; Prachi Bhatnagar; Kremlin Wickramasinghe; Mike Rayner; Melanie Nichols
Journal:  Eur Heart J       Date:  2016-08-14       Impact factor: 29.983

4.  Roles of Angiotensin Peptides and Recombinant Human ACE2 in Heart Failure.

Authors:  Ratnadeep Basu; Marko Poglitsch; Haran Yogasundaram; Jissy Thomas; Brian H Rowe; Gavin Y Oudit
Journal:  J Am Coll Cardiol       Date:  2017-02-21       Impact factor: 24.094

Review 5.  Serelaxin in acute heart failure: Most recent update on clinical and preclinical evidence.

Authors:  Raktim Kumar Ghosh; Kinjal Banerjee; Ramyashree Tummala; Somedeb Ball; Keyvan Ravakhah; Anjan Gupta
Journal:  Cardiovasc Ther       Date:  2017-02       Impact factor: 3.023

Review 6.  GPCR biased ligands as novel heart failure therapeutics.

Authors:  Jonathan D Violin; David G Soergel; Guido Boerrigter; John C Burnett; Michael W Lark
Journal:  Trends Cardiovasc Med       Date:  2013-03-15       Impact factor: 6.677

7.  Angiotensin-neprilysin inhibition versus enalapril in heart failure.

Authors:  John J V McMurray; Milton Packer; Akshay S Desai; Jianjian Gong; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile
Journal:  N Engl J Med       Date:  2014-08-30       Impact factor: 91.245

8.  Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2.

Authors:  Huijun Wei; Seungkirl Ahn; Sudha K Shenoy; Sadashiva S Karnik; László Hunyady; Louis M Luttrell; Robert J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-29       Impact factor: 11.205

9.  First clinical experience with TRV027: pharmacokinetics and pharmacodynamics in healthy volunteers.

Authors:  David G Soergel; Ruth Ann Subach; Conrad L Cowan; Jonathan D Violin; Michael W Lark
Journal:  J Clin Pharmacol       Date:  2013-06-29       Impact factor: 3.126

10.  Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF).

Authors:  Peter S Pang; Javed Butler; Sean P Collins; Gad Cotter; Beth A Davison; Justin A Ezekowitz; Gerasimos Filippatos; Phillip D Levy; Marco Metra; Piotr Ponikowski; John R Teerlink; Adriaan A Voors; David Bharucha; Kathleen Goin; David G Soergel; G Michael Felker
Journal:  Eur Heart J       Date:  2017-08-07       Impact factor: 29.983
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.